Clinical Trial

SNV1521 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Protocol Amendment History 1 change
notable Trial sites expanded: 21 -> 25 locations 2026-06-26
Trial Details
NCT Number NCT06220864
Lead Sponsor Synnovation Therapeutics, Inc.
Conditions Advanced Solid Tumor
Enrollment 400 participants
Start Date 2024-02-23
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-25